Takeda: Cardiovascular Diseases trials
The registry lists 15 Cardiovascular Diseases studies with Takeda as lead sponsor. 0 are open to participants now and 13 have results posted.
Phase 1 1Phase 2 1Phase 3 12No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese VolunteersCompletedNCT02045264Phase 1Results posted
- Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseTerminatedNCT01609582Phase 3Results posted
- Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)CompletedNCT01101035Phase 3Results posted
- Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.CompletedNCT01033071Phase 3Results posted
- Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential HypertensionCompletedNCT00996281Phase 3Results posted
- Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe HypertensionCompletedNCT00847626Phase 3Results posted
- Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe HypertensionCompletedNCT00846365Phase 3Results posted
- Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe HypertensionCompletedNCT00818883Phase 3Results posted
- Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential HypertensionCompletedNCT00760214Phase 3Results posted
- An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.CompletedNCT00696436Phase 3Results posted
- A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedNCT00696384Phase 3Results posted
- Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedNCT00696241Phase 3Results posted
- One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential HypertensionCompletedNCT00695955Phase 3Results posted
- Drug Use Study of Febuxostat After Recent Changes in the Prescribing InformationCompletedNCT04853160
- Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular DiseaseCompletedNCT00770575Phase 2